Advisory Board of Medical Experts Support Use of Nymox Alzheimer Test.

ROCKVILLE, MD--(BUSINESS WIRE)--June 11, 1998--A Medical Advisory Board has been formed for AD7C(TM), Nymox Pharmaceutical Corporation's (NASDAQ National Market: NYMXF; Montreal Exchange: NMX) diagnostic aid to physicians for Alzheimer's Disease ("AD"). The new Board consists of experienced experts in the field who will function as spokespersons to other doctors for Nymox's testing technology, and who will advise on the latest developments in the field. The members of the Board include: Christopher Kircher, MD, Neurologist, Christ Hospital, Cincinnati; George Perry, Ph.D, Professor of Neuropathology, Case Western Reserve University; Philipp Kahle, Ph.D, Neuroscientist, Department of Neurobiology, Stanford University School of Medicine; Douglas M. Brandt, MD, Psychiatrist, Clinical Assistant Professor, Department of Neuropsychiatry & Behavioral Science, University of South Carolina School of Medicine; Ira J. Goodman, MD, Neurologist, Associate Professor of Medicine, University of Florida School of Medicine; Garth Bissette, Ph.D, Professor, Division of Neurobiology & Behavioral Research, University of Mississippi Medical Center; Robert Tureen, Ph.D, Adjunct Associate Professor of Psychology, Miami University of Ohio, and University of Cincinnati; Steven J. Gulevich, MD, Neurologist, Director of Colorado Neurological Institute; John J. Fiebel, MD, Neurologist, Associate Clinical Professor of Neurology, Riverhills Healthcare, Cincinnati, Ohio.

Dr. Michael Munzar, Medical Director of Nymox, commented, "AD7C(TM) is rapidly gaining widespread acceptance among physicians who have used the test or who have carefully examined the data. We are particularly pleased with the high caliber and strong reputations of the experts who are supporting the clinical utilization of the test."

For people with suspicious symptoms but who do not actually have AD, AD7C(TM) testing helps the physician rule out AD and reassure the patient. It also helps the physician find other causes of symptoms which are often successfully treatable such as depression, metabolic disorders, and other conditions. AD7C(TM) testing also forms a biochemical numerical basis for treatment which helps doctors and researchers to evaluate the progress of the disease and the value of new treatments in an objective fashion. AD7C(TM) helps the physician be more confident in the diagnosis of AD, particularly in early cases. All aspects of medical care and family arrangements can be planned more thoroughly and more efficiently. Previously published studies have shown that the early diagnosis of AD on clinical grounds alone is imperfect and takes an average of about 3 years from the time of initial symptoms, which is a long time of inestimable anxiety and anguish for the millions of patients and their families. AD7C(TM) has the potential to streamline and shorten the diagnostic workup for AD and therefore produce significant savings for health care payors.

Nymox Pharmaceutical Corporation is a biopharmaceutical company with several major projects, including a focus on diagnostics and therapeutics for Alzheimer's Disease. In a separate area of Nymox R&D, Nymox researchers recently announced work on "spherons", which was published in the March 1998 Issue of The Journal of Alzheimer's Disease (Volume 1;pages 1-35, also available at http://www.nymox.com.) The Nymox researchers believe that spherons satisfy 20 criteria of validity as a causal entity in AD. Nymox has drug candidates for AD targeted at spherons, which are expected to begin human testing within one year. Nymox is also active in other therapeutic areas, with pre-clinical antibacterial drug candidates.

This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities.

CONTACT: Nymox Corporation NYMXF's INVESTOR RELATIONS COUNSEL:

Michael Munzar, M.D. The Equity Group

Medical Director Devin Sullivan [phone]

(800) 93NYMOX